The Society for Cardiovascular Angiography and Interventions
news & highlights
MAY/JUNE 2016 www.SCAI.org www.SecondsCount.org
CONTINUED ON PAGE 4
In the largest study of its kind, a new device has been found to significantly reduce the volume of radiographic dye without
decreasing image quality in patients who are at risk of developing
acute kidney injury (AKI) after undergoing a coronary angiography
or percutaneous coronary intervention (PCI). The device — known
as AVERT™ — did not, however, reduce contrast-induced AKI
CI-AKI is the sudden deterioration in renal function that can occur after the administration of radiographic dye — or contrast media
volume (CMV) — during an interventional cardiac procedure.
CI-AKI is associated with increased morbidity and mortality, and af-
fects an estimated 20 to 30 percent of patients, particularly those with
diabetes or previous renal impairment. Minimizing CMV in patients
at risk of AKI is a critical preventative measure.
“Physicians are extremely careful about the volume of dye they
administer to patients; the greater the volume, the more problems
a physician can encounter,” said Roxana Mehran, MD, FSCAI,
director of interventional cardiovascular research and clinical tri-
als at the Zena and Michael A. Wiener Cardiovascular Institute,
Icahn School of Medicine at Mount Sinai, and the study’s lead
author. Dr. Mehran also served as SCAI 2016 Program Chair.
With the AVERT system, or device, the operator can control the
volume of dye used during an interventional procedure.
Once the appropriate amount of dye has been injected
New Device Reduces Volume of Radiographic Dye in Patients At
Risk of Developing Acute Kidney Injury
SCAI 2016 LATE-BREAKING CLINICAL TRIALS REPORT